Serum proteomic profiling in patients with drug-induced liver injury

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 5, 2012, Pages 600-612

  Bell, L N ^a   Vuppalanchi, R ^a   Watkins, P B ^b   Bonkovsky, H L ^b,c,d   Serrano, J ^e   Fontana, R J ^f   Wang, M ^a   Rochon, J ^g   Chalasani, N ^a  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c CAROLINAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA 1 ANTITRYPSIN; ALPHA ACTIN; ALPHA SKELETAL MUSCLE ACTIN; AMINOACYLASE; AMYLOID A PROTEIN; AMYLOID A2; AORTIC SMOOTH MUSCLE ACTIN; APOLIPOPROTEIN C; APOLIPOPROTEIN E; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C7; FRUCTOSE BIPHOSPHATE ALDOLASE B; FRUCTOSE BISPHOSPHATE ALDOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE A; FUMARYLACETOACETASE; OBSCURIN; PROTEIN RANBP2; PROTEOME; SCLEROPROTEIN; SERPIN A11; TETRANECTIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CHOLESTATIC HEPATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNE SYSTEM; INFLAMMATION; IRON METABOLISM; LABEL FREE QUNTITATIVE PROTEOMICS; LIVER CELL DAMAGE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROBABILITY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEOMICS; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SIGNAL TRANSDUCTION; TOXIC HEPATITIS;

AGED; BIOLOGICAL MARKERS; BLOOD PROTEINS; CASE-CONTROL STUDIES; DRUG-INDUCED LIVER INJURY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER; LONGITUDINAL STUDIES; MALE; MASS SPECTROMETRY; MIDDLE AGED; PROTEOME; PROTEOMICS; SEVERITY OF ILLNESS INDEX;

EID: 84862777266     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04982.x     Document Type: Article

References (43)

1. Navarro VJ, Senior JR,. Drug-related hepatotoxicity. N Engl J Med 2006; 354: 731-9. (Pubitemid 43247143)
2. Watkins PB, Seeff LB,. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006; 43: 618-31.
3. Abboud G, Kaplowitz N,. Drug-induced liver injury. Drug Saf 2007; 30: 277-94. (Pubitemid 46624528)
4. Bonkovsky HL, Shedlofsky SI, Jones DP, et al,. Drug-induced liver injury. In:, Boyer TD, Manns MP, Sanyal A, eds. Zakim and Boyer's Hepatology-A Textbook of Liver Disease, 6th ed. Philadelphia: Saunders-Elsevier, 2011.
5. Ostapowicz G, Fontana RJ, Schiodt FV, et al,. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-54. (Pubitemid 35440240)
6. Reuben A, Koch DG, Lee WM,. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76.
7. Bjornsson E,. Drug-induced liver injury in clinical practice. Aliment Pharmacol Ther 2010; 32: 3-13.
8. Chalasani N, Bjornsson E,. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010; 138: 2246-59.
9. Au JS, Navarro VJ, Rossi S,. Drug-induced liver injury-its pathophysiology and evolving diagnostic tools. Aliment Pharmacol Ther 2011; 34: 11-20.
10. Fontana RJ, Watkins PB, Bonkovsky HL, et al,. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009; 32: 55-68.
11. Rockey DC, Seeff LB, Rochon J, et al,. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010; 51: 2117-26.
12. Chalasani N, Fontana RJ, Bonkovsky HL, et al,. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34.
13. Vuppalanchi R, Hayashi PH, Chalasani N, et al,. Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther 2010; 32: 1174-83.
14. Orman ES, Conjeevaram HS, Vuppalanchi R, et al,. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol 2011; 9: 517-23.
15. Wang M, You J, Bemis KG, et al,. Label-free mass spectrometry-based protein quantification technologies in proteomic analysis. Brief Funct Genomic Proteomic 2008; 7: 329-39.
16. Bell LN, Theodorakis JL, Vuppalanchi R, et al,. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 2010; 51: 111-20.
17. Bradford MM,. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
18. Hale JE, Butler JP, Gelfanova V, et al,. A simplified procedure for the reduction and alkylation of cysteine residues in proteins prior to proteolytic digestion and mass spectral analysis. Anal Biochem 2004; 333: 174-81. (Pubitemid 39209235)
19. Higgs RE, Knierman MD, Gelfanova V, et al,. Comprehensive label-free method for the relative quantification of proteins from biological samples. J Proteome Res 2005; 4: 1442-50. (Pubitemid 41208703)
20. Craig R, Beavis RC,. TANDEM: matching proteins with tandem mass spectra. Bioinformatics 2004; 20: 1466-7. (Pubitemid 38931421)
21. Eng J, McCormack A, Yates RR,. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 1994; 5: 976-89.
22. Higgs RE, Knierman MD, Freeman AB, et al,. Estimating the statistical significance of peptide identifications from shotgun proteomics experiments. J Proteome Res 2007; 6: 1758-67. (Pubitemid 46814500)
23. Bolstad BM, Irizarry RA, Astrand M, et al,. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19: 185-93. (Pubitemid 36181903)
24. Tujios S, Fontana RJ,. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol 2011; 8: 202-11.
25. Kienhuis AS, Bessems JG, Pennings JL, et al,. Application of toxicogenomics in hepatic systems toxicology for risk assessment: acetaminophen as a case study. Toxicol Appl Pharmacol 2011; 250: 96-107.
26. Ellinger-Ziegelbauer H, Adler M, Amberg A, et al,. The enhanced value of combining conventional and "omics" analyses in early assessment of drug-induced hepatobiliary injury. Toxicol Appl Pharmacol 2011; 252: 97-111.
27. Lewis JA, Dennis WE, Hadix J, et al,. Analysis of secreted proteins as an in vitro model for discovery of liver toxicity markers. J Proteome Res 2010; 9: 5794-802.
28. Shimada T, Nakanishi T, Toyama A, et al,. Potential implications for monitoring serum bile acid profiles in circulation with serum proteome for carbon tetrachloride-induced liver injury/regeneration model in mice. J Proteome Res 2010; 9: 4490-500.
29. Wang Y, Yang B, Wu C, et al,. Plasma and liver proteomic analysis of 3Z-3-[(1H-pyrrol-2-yl)-methylidene]-1-(1-piperidinylmethyl)-1, 3-2H-indol-2-one-induced hepatotoxicity in Wistar rats. Proteomics 2010; 10: 2927-41.
30. Andersson U, Lindberg J, Wang S, et al,. A systems biology approach to understanding elevated serum alanine transaminase levels in a clinical trial with ximelagatran. Biomarkers 2009; 14: 572-86.
31. Jia N, Liu X, Wen J, et al,. A proteomic method for analysis of CYP450s protein expression changes in carbon tetrachloride induced male rat liver microsomes. Toxicology 2007; 237: 1-11. (Pubitemid 47033948)
32. Craig A, Sidaway J, Holmes E, et al,. Systems toxicology: integrated genomic, proteomic and metabonomic analysis of methapyrilene induced hepatotoxicity in the rat. J Proteome Res 2006; 5: 1586-601. (Pubitemid 44036133)
33. Merrick BA, Bruno ME, Madenspacher JH, et al,. Alterations in the rat serum proteome during liver injury from acetaminophen exposure. J Pharmacol Exp Ther 2006; 318: 792-802. (Pubitemid 44061253)
34. Rodriguez-Ariza A, Lopez-Sanchez LM, Gonzalez R, et al,. Altered protein expression and protein nitration pattern during d-galactosamine-induced cell death in human hepatocytes: a proteomic analysis. Liver Int 2005; 25: 1259-69. (Pubitemid 41786701)
35. Amacher DE, Adler R, Herath A, et al,. Use of proteomic methods to identify serum biomarkers associated with rat liver toxicity or hypertrophy. Clin Chem 2005; 51: 1796-803. (Pubitemid 41368169)
36. Welch KD, Wen B, Goodlett DR, et al,. Proteomic identification of potential susceptibility factors in drug-induced liver disease. Chem Res Toxicol 2005; 18: 924-33. (Pubitemid 40880881)
37. Kleno TG, Kiehr B, Baunsgaard D, et al,. Combination of 'omics' data to investigate the mechanism(s) of hydrazine-induced hepatotoxicity in rats and to identify potential biomarkers. Biomarkers 2004; 9: 116-38. (Pubitemid 39268768)
38. O'Connell TM, Watkins PB,. The application of metabonomics to predict drug-induced liver injury. Clin Pharmacol Ther 2010; 88: 394-9.
39. Cui Y, Paules RS,. Use of transcriptomics in understanding mechanisms of drug-induced toxicity. Pharmacogenomics 2010; 11: 573-85.
40. Scott CR,. The genetic tyrosinemias. Am J Med Genet C Semin Med Genet 2006; 142C: 121-6.
41. Maniratanachote R, Shibata A, Kaneko S, et al,. Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction. Toxicology 2005; 216: 15-23. (Pubitemid 41531254)
42. Laverty HG, Antoine DJ, Benson C, et al,. The potential of cytokines as safety biomarkers for drug-induced liver injury. Eur J Clin Pharmacol 2010; 66: 961-76.
43. Ferre N, Martinez-Clemente M, Lopez-Parra M, et al,. Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols. Am J Physiol Gastrointest Liver Physiol 2009; 296: G553-62.